This protocol describes how to assess synergism between an anticancer antibody and antineoplastic drugs in preclinical models by using the combination index equation of Chou and Talalay.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
This protocol describes how to assess synergism between an anticancer antibody and antineoplastic drugs in preclinical models by using the combination index equation of Chou and Talalay.
Potentiation of hostile monoclonal antibodies (mAb) by chemotherapeutic agents constitutes a valuable strategy for designing effective and safer therapy against cancer. Here we provide a protocol to identify a rational combination at the preclinical step. First, we describe a cell-based assay to assess the synergism between anticancer mAb and cytotoxic drugs, that uses the combination index equation of Chou and Talalay1. This includes the measurement of tumor cell drug- and antibody-sensitivity using an MTT assay, followed by an automated computer analysis to calculate the combination index (CI) values. CI values of <1 indicate synergism between tested mAbs and cytotoxic agents1. To corroborate the in vitro findings in vivo, we further describe a method to assess the combination regimen efficacy in a xenograft tumor model. In this model, the combined regimen significantly delays tumor growth, which results in a significant extended survival in comparison to single-agent controls. Importantly, the in vivo experimentation reveals that the combination regimen is well tolerated. This protocol allows the effective evaluation of anticancer drug combinations in preclinical models and the identification of rational combination to evaluate in clinical trials.
The conventional approach in the treatment of a large number of different types of cancer was based on monotherapy. Even if it is still used in many cases, this method met several obstacles leading to opting for combined therapies2. Particularly, cancer cells are more susceptible to develop resistance when treated with a single drug by inducing alternative survival mechanisms3, resulting in therapeutic failure in patients4. Moreover, in monotherapy, drugs are usually administrated at a high dose. This situation often results in the occurrence of strong dose-dependent side effects that can be intol....
Access restricted. Please log in or start a trial to view this content.
Animal housing and experimental procedure were approved by the French Government (agreements #C44-278 and #APAFIS 03479.01). Animal care and procedures were conducted under directive EU 2010/63/EU and French Law #2013-118 on the protection of animals used for scientific purposes.
1. Evaluation of the Drug Interaction Between mAb 8B6 and Topotecan In Vitro
Access restricted. Please log in or start a trial to view this content.
The representative results and figures are adapted with permission from earlier published work14.
Anti-OAcGD2 mAb 8B6 Synergistically Enhances the Inhibitory Effects of Topotecan on Neuroblastoma Cell Line Growth:
To establish the drug and the antibody concentrations to be used for assessing synergism between topotecan and mAb 8.......
Access restricted. Please log in or start a trial to view this content.
To predict the effect of drug interactions, three methods can be used: the isobologram methodology17, the nonlinear mixture model18, and the combination index1. Combination index analysis is the most commonly used because its application is simplified by the availability of a user-friendly computer program. For this purpose, we first characterized the dose-effect response of each agent used alone or in combination, by performing an MTT assay
Access restricted. Please log in or start a trial to view this content.
S.Fa., J.F., and S.B. are designated as inventors of pending patents covering the clinical application of anti-O-acetyl-GD2 therapeutic antibodies.
Grant support: Fondation de Projet de L'Université de Nantes, les Bagouz' à Manon, La Ligue contre le Cancer comité de Loire-Atlantique, comité du Morbihan, and comité de Vendée, une rose pour S.A.R.A.H, L'Etoile de Martin and la Société Française de Lutte contre les Cancers et les leucémies de L'Enfant et de L'adolescent (SFCE). M.B. and J.F. are supported by La Ligue Contre Le Cancer. The authors thank the UTE-facility of the Structure Fédérative de Recherche François Bonamy. The authors also thank Dr. S. Suzin (Inserm, Paris) for providing the IMR5 cells and Ms. H. Estéph....
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Cell Proliferation kit (MTT) | Roche | 11-465-007-001 | |
| CompuSyn software | ComboSyn | Combosyn can be downloaded for free at http://www.combosyn.com | |
| Electric shaver | Bioseb | BIO-1556 | |
| Fetal calf serum | Eurobio | CVFSVFF00-01 | 10% heat-inactivated fetal calf serum in RPMI 1640 |
| Firefox | Mozilla Corporation | Firefox can be downloaded for free at http://www.mozilla.org/en-US/firefox/ | |
| Heat lamp | Verre&Quartz | 4003/1R | |
| Human neuroblastoma IMR-5 cell line | Accegen Biotechnology | ABC-TC0450 | IMR-5 is a clone of the human neuroblastoma cell line IMR32 5459762. IMR-5 cells were generously provided by Dr. Santos Susin (U.872, Paris, France) |
| L-glutamine | Gibco | 25030-024 | 2 mM in RPMI 1640 |
| Lysis solution | Roche | 11-465-007-001 | |
| mAb 8B6 | University of Nantes | N/A | |
| Matrigel | Corning | 354248 | |
| Multiskan FC | Thermofischer Scientific | N08625 | |
| Needle 21G 1 ½ | BD Microlance | 304432 | |
| Needle 25G 1 | Terumo | NN-2525R | |
| NSG mice | Charles River Laboratories | 5557 | |
| Nunc MicroWell 96-well microplates | Thermofisher | 167008 | |
| PBS | VWR | L182-10 | |
| PBS, 0,05% EDTA | Sigma-Aldrich | E9884 | |
| PC that runs windows 7 | Microsoft | Windows 7 can be purchased at http://www.microsoft.com/en-gb/software-download/windows7 | |
| Penicillin-Streptomycin | Gibco | 15140-122 | 100 units/mL penicillin and 100 mg/mL streptomycin in RPMI 1640 |
| Reagent reservoir | Thermofischer Scientific | 8094 | |
| Rodent restrainer | Bioseb | TV-150-SM | |
| RPMI 1640 | Gibco | 31870-025 | |
| Syringe 1 mL | Henke Sass Wolf | 5010.200V0 | |
| Topotecan | Sigma-Aldrich | T2705 |
Access restricted. Please log in or start a trial to view this content.